Pretreatment of patients requiring oral contrast abdominal computed tomography with antiemetics: a randomized controlled trial of efficacy
| Autor: | Jasmine Chohan, Gregory Garra, Regina M. Troxell, Henry C. Thode, Adam J. Singer, Danny Bamber |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Radiography Abdominal Metoclopramide medicine.drug_class Nausea Vomiting Administration Oral Contrast Media Placebo Ondansetron Double-Blind Method Intensive care Medicine Antiemetic Humans Diatrizoate Meglumine Analysis of Variance Chi-Square Distribution business.industry Middle Aged Treatment Outcome Anesthesia Emergency Medicine Antiemetics Female medicine.symptom business Tomography X-Ray Computed medicine.drug |
| Zdroj: | Annals of emergency medicine. 53(4) |
| ISSN: | 1097-6760 |
| Popis: | Study objective Ingestion of diatrizoate meglumine before abdominal computed tomography (CT) is time consuming. We hypothesized that pretreatment with metoclopramide or ondansetron would result in faster ingestion of diatrizoate meglumine than placebo. Methods The study was a double-blind, randomized controlled trial on adults requiring oral contrast abdominal CT. Patients were randomized to placebo, metoclopramide 10 mg, or ondansetron 4 mg intravenously 15 minutes before ingesting 2 L of diatrizoate meglumine. The primary outcome was time to complete diatrizoate meglumine ingestion. Secondary outcome measures included volume of diatrizoate meglumine ingested, 100-mm visual analog scale for nausea at 15-minute intervals, time to CT, vomiting, and use of rescue antiemetics. The study was powered to detect a 60-minute difference in diatrizoate meglumine ingestion time between saline and medication groups. Results One hundred six patients were randomized; placebo (36), metoclopramide (35), and ondansetron (35). Groups were similar in baseline characteristics. Median (interquartile range) times for diatrizoate meglumine ingestion were placebo 109 minutes (82 to 135 minutes); metoclopramide 105 minutes (75 to 135 minutes); and ondansetron 110 minutes (79 to 140 minutes) (P=.67). Vomiting was less frequent with metoclopramide (3%) than placebo (18%) or ondansetron (9%) (P=.11). The visual analog scale for nausea at each point was not significantly different between groups (P=.11). The need for rescue antiemetics was lowest for metoclopramide (3%) compared with placebo (27%) and ondansetron (12%) (P=.02). Conclusion Pretreatment with ondansetron or metoclopramide does not reduce oral contrast solution ingestion time. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect